Chimeric antigen receptors (CARs) are engineered receptors that mediate T cell activation.
CARs are comprised of activating and co-stimulatory intracellular signaling domains derived …

Purpose In previous research, we have found that LMP1-specific chimeric antigen
(HELA/CAR) T cells can specifically recognize and kill LMP1-positive NPC cells. However …

Malignant pleural mesothelioma (MPM) has been marked historically by poor prognosis.
Current standard of care for this deadly disease results in sub-optimal improvements in …

Malignant gliomas (MG) are the most common type of primary malignant brain tumor. Most
patients diagnosed with glioblastoma (GBM), the most common and malignant glial tumor …

Tumor vaccines, an important part of immunotherapy, prevent cancer or kill existing tumor
cells by activating or restoring the body's own immune system. Currently, various …

Adoptive immunotherapy using genetically modified T-cells with a chimeric antigen receptor
(CAR) is a promising modality for cancer treatment, because the CAR-grafted T-cells can …

A major challenge in developing an effective adoptive cancer immunotherapy is the ex-vivo
generation of tumor-reactive cells in sufficient numbers and with enhanced cytotoxic …

Folate receptor alpha (FRα) is aberrantly expressed in ovarian cancers but largely absent in
normal tissues, and therefore represents an attractive target for immunotherapy. In recent …

A transformed T-cell for T-cell therapy, and a composition including the same for anticancer
immunotherapy. More particularly, the transformed T-cell is characterized by the transfection …

As a common malignant tumor, hepatocellular carcinoma (HCC) has high fatality rate due to
its strong metastasis and high degree of malignancy. Current treatment strategies adopted in …